Gerald Appel

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria

Hulin Jin, J. Barratt, J. Tumlin, 2022, Kidney international reports.

The Renal and Urologic Complications of Inflammatory Bowel Disease

H. El‐Serag, F. Zwas, N. Cirillo, 1997, Inflammatory bowel diseases.

Exercise acutely increases renal transit time of Tc-99m mercaptoacetyltriglycine (MAG3) in a post-liver transplant patient.

R. V. Van Heertum, R. Tikofsky, S. Bergmann, 2006, Clinical nuclear medicine.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Clinical trial recommendations for potential Alport syndrome therapies

Anne R. Pariser, C. Baigent, M. Prunotto, 2020, Kidney international.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.